Insights on the Current and Future Trends of the E-cigarette Supply Chain

Aug.21.2023
Insights on the Current and Future Trends of the E-cigarette Supply Chain
2FIRSTS Releases E-Cigarette Supply Chain Survey Report on Industry Trends and Performance in First Half of 2023.

As the e-cigarette industry continues to flourish, both the industry itself and the public have gained a deeper understanding of the e-cigarette supply chain. In order to gain a comprehensive understanding of the various aspects of the e-cigarette supply chain and investigate its current state, 2FIRSTS released a survey on the e-cigarette supply chain for the first half of 2023 on July 10th.


The investigation covered the current state and future prospects of supply chain companies in the e-cigarette industry. A total of 45 valid questionnaires were received, providing valuable information for the e-cigarette supply chain. Through the analysis of these data, a series of results reflecting the current industry status and future trends were obtained, which have been compiled into a report for this survey.


Outstanding performance in the first half of the year.


According to the data, more than 60% of companies achieved growth in the first half of 2023, with 11.9% even exceeding expectations. On the other hand, 19.0% of companies experienced a decline in performance as expected, while 16.7% saw a performance decline that surpassed expectations.


Optimistic Outlook for the Future of the Middle Eastern Market


In terms of market outlook for the second half of 2023, the Middle East market has received the highest rating with an average score of 4.05. Following closely behind are the Southeast Asia, Continental Europe, UK, and US markets, with scores of 3.61, 3.58, 3.41, and 3.05 respectively. However, supply chain companies have expressed a pessimistic outlook for the Russian market, giving it a meager score of 2.72.


The global atomization market is expected to continue to grow.


More than 80% of e-cigarette supply chain companies believe that the global vaporization market will continue to grow in the second half of the year. Among them, 17.8% of companies predict high growth in the market, while less than 20% of companies believe that the market will either maintain low growth or not grow at all.


The policy represents the instability of the e-cigarette market.


According to a survey, 40% of e-cigarette supply chain companies believe that the policies implemented by various countries have had a negative impact on their performance expectations. On the other hand, 33.3% of companies believe that these policies have not had a significant impact, while 26.7% believe that they have had a positive impact.


Innovative disposable e-cigarettes have become the center of attention.


In terms of product categories, disposable e-cigarettes and innovative disposable e-cigarettes have become the focus of attention for supply chain companies in the second half of 2023. However, depending on the region, the American and British markets show higher interest in innovative disposable e-cigarettes compared to disposable e-cigarettes. In the European continental market, the level of interest in various categories of e-cigarettes is similar, while the Southeast Asian, Middle Eastern, and Russian markets primarily focus on disposable e-cigarettes.


The above is a section of the survey conducted by 2FIRSTS on the e-cigarette supply chain. If you would like to obtain the complete version of the survey report and gain a detailed understanding of the current status and future trends of the e-cigarette supply chain, please click on the link below to access the full report.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea Imports 12,126 Kg of Nicotine Analogues From April to August After Bringing Synthetic Nicotine Under Tobacco Law
South Korea's liquid-vape market is showing changes across raw-material imports, product types and sales channels after synthetic nicotine came under the Tobacco Business Act on April 24. Customs data show nicotine-analogue imports totaled 12,126 kilograms from April through August, while synthetic-nicotine imports over the same five months totaled 231,663 kilograms, just 39.3% of the amount imported in March alone. Physical liquid-vape stores tracked in Seoul and Gyeonggi Province fell 9.9%, unmanned outlets edged higher and online sales listings increased from 27,774 to 42,437. Government testing of 105 liquid inhalation products promoted as nicotine-free separately found nicotine in 13 and 6-methylnicotine in 12.
Sep.22
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
2Firsts On-Site | PMI Brings IQOS, ZYN, VEEV and Marlboro Together at Its “Boulevard” at InterTabac 2026
At InterTabac 2026 in Dortmund, PMI is presenting multiple brands and products along “The PMI Boulevard,” including IQOS, ZYN, VEEV and Marlboro. On-site images captured by 2Firsts show dedicated spaces including the IQOS Boutique, ZYN Café, PMI Gallery and Marlboro Office
Market
Sep.16 by 2Firsts Perspectives
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
UK Extends Age-18 Rules to Zero-Nicotine Vapes and Nicotine Pouches From Oct. 29, Bans Vending Machines and Promotional Giveaways
Key provisions of the UK's Tobacco and Vapes Act 2026 will take effect on Oct. 29, extending an age-18 sales restriction to all vaping and non-medicinal nicotine products. In England, Wales and Northern Ireland, the change brings zero-nicotine vapes within statutory age-of-sale rules and also covers products including nicotine pouches, strips and pearls. The law will also prohibit proxy purchasing for under-18s, consumer-facing vending machines, promotional giveaways and substantial discounts intended to promote vaping and nicotine products.
Regulations
Oct.10
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
BAT CFO Dragos Constantinescu Takes Office, Returning After Seven Years and Former Asahi Europe Leadership Role
Dragos Constantinescu has officially taken up his role as Chief Financial Officer and Executive Director at British American Tobacco (BAT). He previously spent 16 years at BAT across finance and general management roles in Europe before joining Asahi in 2019 and becoming CEO of Asahi Europe & International in 2025. His return comes as BAT continues to advance its “A Better Tomorrow” transformation.
BAT
Sep.01
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?
SCIENCE
Sep.23